Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PSMB10 | P40306 | 2/20 | 0.40 |
| ▸ | PSMB2 | P49721 | 2/20 | 0.40 |
| ▸ | MASP2 | O00187 | 3/20 | 0.40 |
| ▸ | FURIN | P09958 | 1/20 | 0.37 |
| ▸ | CPB2 | Q96IY4 | 6/20 | 0.35 |
| ▸ | CPB1 | P15086 | 2/20 | 0.35 |
| ▸ | F2 | P00734 | 1/20 | 0.34 |
| ▸ | F10 | P00742 | 1/20 | 0.34 |
| ▸ | F2RL1 | P55085 | 2/20 | 0.34 |
| ▸ | TLR2 | O60603 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1431923 | 1.00 | PSMB10 (0.40) | PSMB10PSMB2MASP2FURINCPB2 | |
| SCHEMBL1903263 | 0.92 | MASP2 (0.40) | PSMB10PSMB2MASP2FURINCPB2 | |
| SCHEMBL1903269 | 0.92 | MASP2 (0.40) | PSMB10PSMB2MASP2FURINCPB2 | |
| SCHEMBL1907760 | 0.90 | PSMB10 (0.41) | PSMB10PSMB2MASP2FURINCPB2 | |
| SCHEMBL1432775 | 0.90 | PSMB10 (0.39) | PSMB10PSMB2MASP2FURINCPB2 | |
| SCHEMBL1907759 | 0.90 | PSMB10 (0.41) | PSMB10PSMB2MASP2FURINCPB2 | |
| SCHEMBL3141239 | 0.90 | PSMB10 (0.39) | PSMB10PSMB2MASP2FURINCPB2 | |
| SCHEMBL1902808 | 0.89 | MAPK1 (0.40) | PSMB10PSMB2MASP2CPB2CPB1 | |
| SCHEMBL1432229 | 0.88 | MASP2 (0.43) | PSMB10PSMB2MASP2FURINCPB2 | |
| SCHEMBL1907930 | 0.88 | MASP2 (0.41) | PSMB10PSMB2MASP2FURINCPB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2300428-A1 | AMINOPYRIDINE DERIVATIVES | Vantia Limited (GB) | 2011-03-30 | — | — | EP | disclosed |
| US-20100076015-A1 | Aminopyridine Derivatives | VANTIA LIMITED (GB) | 2010-03-25 | — | — | US | disclosed |
| WO-2009133348-A1 | AMINOPYRIDINE DERIVATIVES | VANTIA LIMITED (GB) | 2009-11-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100076015-A1 | Aminopyridine Derivatives | CHRM1, ARG1, ARG2 | PSMB10 2852/4885PSMB2 2867/4885MASP2 3039/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.